Eli Lilly announced that the Phase 3 LIBRETTO-432 trial of Retevmo (selpercatinib) significantly improved event-free survival by reducing the risk of recurrence or death by 83% compared to placebo in early-stage RET fusion-positive non-small cell lung cancer patients. This is the first proven targeted adjuvant therapy for this patient group, highlighting the need for comprehensive biomarker testing at diagnosis. The results, to be published in the New England Journal of Medicine and presented at the 2026 ASCO Annual Meeting, may change clinical practice by establishing Retevmo as a new standard of care after surgery or radiation.
Eli Lilly announced that CVS Caremark will add its GLP-1 medications, including the new pill Foundayo and injection Zepbound, to their formularies starting next week. This move could allow millions of Americans to access these drugs if their employer...
Eli Lilly continues to outperform revenue expectations and is expanding its drug pipeline through strategic acquisitions in infectious diseases and other areas. While new infectious disease treatments like amezosvatein show promise, significant reven...
Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss ...
CVS Health will restore coverage of Eli Lilly's weight loss injection Zepbound starting October 1 and begin covering Lilly's new obesity pill Foundayo from June 1 on its standard drug plans. This move balances coverage between Eli Lilly and Novo Nord...
Eli Lilly announced that CVS Caremark will begin covering its obesity drug Foundayo starting June 1 and will resume coverage for Zepbound by October 1, making these treatments more accessible through major pharmacy benefit managers. Eligible patients...
